BTI.V Stock - Bioasis Technologies Inc.
Unlock GoAI Insights for BTI.V
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $37,725 | $4.08M | $606,384 | $1.42M | $589,844 |
| Gross Profit | $-17,192 | $4.08M | $606,384 | $1.41M | $121,976 |
| Gross Margin | -45.6% | 100.0% | 100.0% | 99.3% | 20.7% |
| Operating Income | $-4,887,678 | $-83,305 | $-5,193,850 | $-6,239,149 | $-5,235,216 |
| Net Income | $-2,960,092 | $698,410 | $-4,056,420 | $-3,473,414 | $-5,307,938 |
| Net Margin | -7846.5% | 17.1% | -669.0% | -244.3% | -899.9% |
| EPS | $-0.04 | $0.01 | $-0.07 | $-0.06 | $-0.10 |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
Visit WebsiteEarnings History & Surprises
BTI.VEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Feb 3, 2025 | — | — | — | — |
Q2 2024 | May 1, 2024 | — | — | — | — |
Q2 2024 | May 1, 2024 | — | — | — | — |
Q1 2024 | Jan 19, 2024 | — | — | — | — |
Q4 2023 | Oct 27, 2023 | — | — | — | — |
Q3 2023 | Jul 27, 2023 | — | — | — | — |
Q1 2023 | Jan 19, 2023 | $-0.01 | $-0.01 | 0.0% | = MET |
Q4 2022 | Oct 28, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 14, 2022 | $-0.01 | $-0.01 | -49.9% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | — | $-0.01 | — | — |
Q1 2022 | Jan 20, 2022 | $-0.02 | $-0.02 | 0.0% | = MET |
Q4 2021 | Oct 28, 2021 | $-0.01 | $-0.01 | 0.0% | = MET |
Q2 2021 | Jun 25, 2021 | $-0.01 | $-0.01 | -49.9% | ✗ MISS |
Q1 2021 | Feb 28, 2021 | — | $-0.02 | — | — |
Q1 2021 | Jan 27, 2021 | $-0.01 | $-0.01 | 0.0% | = MET |
Q3 2020 | Aug 31, 2020 | — | $0.03 | — | — |
Q3 2020 | Jul 27, 2020 | — | $-0.02 | — | — |
Q1 2020 | Jan 29, 2020 | — | $-0.02 | — | — |
Q4 2019 | Nov 30, 2019 | — | $-0.01 | — | — |
Q4 2019 | Oct 25, 2019 | — | $-0.02 | — | — |
Latest News
Frequently Asked Questions about BTI.V
What is BTI.V's current stock price?
What is the analyst price target for BTI.V?
What sector is Bioasis Technologies Inc. in?
What is BTI.V's market cap?
Does BTI.V pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BTI.V for comparison